In our series “The Cost of Denial,” NBC News’ Erin McLaughlin reports on a West Virginia family’s appeal after appeal to get insurance coverage for a treatment called histotripsy which uses ultrasound ...

A new target for potential treatments for blast phase myeloproliferative neoplasm (BP-MPN), one of the most aggressive forms ...

Mwende was diagnosed with stage 0 breast cancer during a routine check-up. She had no family history, no warning signs. She ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

A clinical trial at MSK found that music therapy for cancer-related anxiety is as effective as cognitive behavioral therapy and produces long-lasting benefits. Dr. Kevin Liou presented the results of ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

SHA-registered beneficiaries will now have full coverage for treatment cycles costing up to Sh700,000 annually.

Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate, a new class of drug that is designed to more precisely target and kill cancer ... breast cancer in combination with Herceptin ...

With the advent of targeted therapy, survival rates have improved. In 1998, Herceptin (trastuzumab), the first medication to directly target HER2, was approved by the FDA. Oncologists usually start ...